Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | BRD2 | P25440 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 6/20 | 0.36 |
| ▸ | MIF | P14174 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13435285 | 0.85 | KCNJ1 (0.40) | KCNJ1BRD4BRD2NOTUMMIF | |
| SCHEMBL21424267 | 0.83 | EPHX2 (0.48) | GBA1 | |
| SCHEMBL17133298 | 0.83 | MALT1 (0.43) | KCNJ1LMNABRD4BRD2NOTUM | |
| SCHEMBL17369045 | 0.82 | GLS (0.45) | GLSKDM4ELMNARAB9AGBA1 | |
| SCHEMBL15336482 | 0.81 | KCNJ1 (0.41) | KCNJ1BRD4BRD2NOTUMMIF | |
| SCHEMBL9891847 | 0.80 | GLS (0.41) | GLSKDM4ELMNARAB9ANOTUM | |
| SCHEMBL20997046 | 0.80 | PARP14 (0.41) | GLSKDM4ELMNARAB9ANOTUM | |
| SCHEMBL22917015 | 0.79 | KCNJ1 (0.40) | KCNJ1 | |
| SCHEMBL13872481 | 0.79 | KCNJ1 (0.56) | KCNJ1KDM4ELMNARAB9ABRD4 | |
| SCHEMBL25123070 | 0.78 | GLS (0.48) | GLSGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024112612-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20100069607-A1 | METHOD OF COVALENTLY LINKING A CARBOHYDRATE OR POLYALKYLENE OXIDE TO A PEPTIDE, PRECURSORS FOR USE IN THE METHOD AND RESULTANT PRODUCTS | UCL BUSINESS PLC (GB) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069607-A1 | METHOD OF COVALENTLY LINKING A CARBOHYDRATE OR POLYALKYLENE OXIDE TO A PEPTIDE, PRECURSORS FOR USE IN THE METHOD AND RESULTANT PRODUCTS | MSR1, C9, ADM2 | GLS 2827/4885KCNJ1 3366/4885KDM4E 2266/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | GLS 1411/4885KCNJ1 4767/4885KDM4E 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.